HRP20110840T1 - Postupak predviđanja osjetljivosti na farmaceutsku terapiju pretilosti - Google Patents
Postupak predviđanja osjetljivosti na farmaceutsku terapiju pretilosti Download PDFInfo
- Publication number
- HRP20110840T1 HRP20110840T1 HR20110840T HRP20110840T HRP20110840T1 HR P20110840 T1 HRP20110840 T1 HR P20110840T1 HR 20110840 T HR20110840 T HR 20110840T HR P20110840 T HRP20110840 T HR P20110840T HR P20110840 T1 HRP20110840 T1 HR P20110840T1
- Authority
- HR
- Croatia
- Prior art keywords
- patient
- trl
- response
- pharmaceutical
- fat
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 8
- 208000008589 Obesity Diseases 0.000 title claims 7
- 235000020824 obesity Nutrition 0.000 title claims 7
- 238000002560 therapeutic procedure Methods 0.000 title claims 3
- 230000004043 responsiveness Effects 0.000 title 1
- 230000004580 weight loss Effects 0.000 claims abstract 19
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract 3
- 208000016261 weight loss Diseases 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 239000012472 biological sample Substances 0.000 claims 7
- 206010033307 Overweight Diseases 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims 1
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 claims 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 1
- 229940086609 Lipase inhibitor Drugs 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 108091006082 receptor inhibitors Proteins 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 230000008604 lipoprotein metabolism Effects 0.000 abstract 2
- 238000004590 computer program Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1488107P | 2007-12-19 | 2007-12-19 | |
| PCT/US2008/087367 WO2009085917A1 (en) | 2007-12-19 | 2008-12-18 | Method for predicting responsiveness to a pharmaceutical therapy for obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110840T1 true HRP20110840T1 (hr) | 2011-12-31 |
Family
ID=40386209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110840T HRP20110840T1 (hr) | 2007-12-19 | 2011-11-14 | Postupak predviđanja osjetljivosti na farmaceutsku terapiju pretilosti |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8084261B2 (da) |
| EP (2) | EP2235544A1 (da) |
| JP (1) | JP5242701B2 (da) |
| KR (2) | KR101240875B1 (da) |
| AT (1) | ATE530916T1 (da) |
| AU (2) | AU2008343187A1 (da) |
| BR (2) | BRPI0821051B1 (da) |
| CA (2) | CA2710248A1 (da) |
| CY (1) | CY1112352T1 (da) |
| DK (1) | DK2238458T3 (da) |
| ES (1) | ES2373625T3 (da) |
| HR (1) | HRP20110840T1 (da) |
| MX (1) | MX2010006890A (da) |
| PL (1) | PL2238458T3 (da) |
| PT (1) | PT2238458E (da) |
| SI (1) | SI2238458T1 (da) |
| WO (2) | WO2009085917A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2457098B1 (en) * | 2009-07-22 | 2014-08-13 | Eli Lilly and Company | Method for predicting weight gain associated with a pharmaceutical therapy |
| US20160131603A1 (en) * | 2013-06-18 | 2016-05-12 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Methods of predicting of chemical properties from spectroscopic data |
| WO2016065463A1 (en) * | 2014-10-28 | 2016-05-06 | 2352409 Ontario Inc. | Methods for providing personalized diet and activity recommendations that adapt to the metabolism of each dieter individually using frequent measurements of activity and triglyceride levels |
| KR102397234B1 (ko) | 2020-09-17 | 2022-05-12 | 가천대학교 산학협력산 | 약물 순응도 평가 방법 및 시스템 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2384292A (en) | 1991-07-30 | 1993-03-02 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
| FR2767135B1 (fr) * | 1997-08-06 | 2002-07-12 | Genset Sa | Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes |
| AU2054000A (en) | 1999-02-26 | 2000-09-14 | Lipomed, Inc. | Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood |
| WO2003012416A1 (en) | 2001-08-01 | 2003-02-13 | Liposcience, Inc. | Method of determining presence and concentration of lipoprotein x in blood plasma and serum |
| CA2477614A1 (en) * | 2002-03-05 | 2003-09-18 | Merck & Co., Inc. | Biomarker for efficacy of appetite suppressant drugs |
| WO2005098463A2 (en) * | 2004-04-01 | 2005-10-20 | Liposcience, Inc. | Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples |
| WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| EP1876448A1 (en) * | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
-
2008
- 2008-12-18 PL PL08867898T patent/PL2238458T3/pl unknown
- 2008-12-18 KR KR1020107013587A patent/KR101240875B1/ko active IP Right Grant
- 2008-12-18 MX MX2010006890A patent/MX2010006890A/es active IP Right Grant
- 2008-12-18 AU AU2008343187A patent/AU2008343187A1/en not_active Abandoned
- 2008-12-18 US US12/743,029 patent/US8084261B2/en active Active
- 2008-12-18 WO PCT/US2008/087367 patent/WO2009085917A1/en active Application Filing
- 2008-12-18 WO PCT/US2008/087386 patent/WO2009085927A1/en active Application Filing
- 2008-12-18 BR BRPI0821051-9A patent/BRPI0821051B1/pt active IP Right Grant
- 2008-12-18 JP JP2010539782A patent/JP5242701B2/ja active Active
- 2008-12-18 CA CA2710248A patent/CA2710248A1/en not_active Abandoned
- 2008-12-18 EP EP08866409A patent/EP2235544A1/en not_active Withdrawn
- 2008-12-18 KR KR1020107013606A patent/KR20100088624A/ko not_active Application Discontinuation
- 2008-12-18 CA CA2710395A patent/CA2710395C/en active Active
- 2008-12-18 DK DK08867898.2T patent/DK2238458T3/da active
- 2008-12-18 SI SI200830495T patent/SI2238458T1/sl unknown
- 2008-12-18 BR BRPI0821364-0A patent/BRPI0821364A2/pt not_active IP Right Cessation
- 2008-12-18 AT AT08867898T patent/ATE530916T1/de active
- 2008-12-18 US US12/743,034 patent/US8355877B2/en active Active
- 2008-12-18 AU AU2008343177A patent/AU2008343177B2/en active Active
- 2008-12-18 ES ES08867898T patent/ES2373625T3/es active Active
- 2008-12-18 EP EP08867898A patent/EP2238458B1/en active Active
- 2008-12-18 PT PT08867898T patent/PT2238458E/pt unknown
-
2011
- 2011-11-14 HR HR20110840T patent/HRP20110840T1/hr unknown
- 2011-12-02 CY CY20111101197T patent/CY1112352T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2710248A1 (en) | 2009-07-09 |
| DK2238458T3 (da) | 2012-01-23 |
| BRPI0821051A2 (pt) | 2015-06-16 |
| KR20100088624A (ko) | 2010-08-09 |
| EP2235544A1 (en) | 2010-10-06 |
| KR20100084577A (ko) | 2010-07-26 |
| US8355877B2 (en) | 2013-01-15 |
| BRPI0821364A2 (pt) | 2015-06-16 |
| ES2373625T3 (es) | 2012-02-07 |
| WO2009085927A1 (en) | 2009-07-09 |
| JP5242701B2 (ja) | 2013-07-24 |
| ATE530916T1 (de) | 2011-11-15 |
| MX2010006890A (es) | 2010-09-30 |
| US20100248375A1 (en) | 2010-09-30 |
| US8084261B2 (en) | 2011-12-27 |
| PT2238458E (pt) | 2012-01-11 |
| AU2008343177B2 (en) | 2013-09-26 |
| KR101240875B1 (ko) | 2013-03-08 |
| EP2238458B1 (en) | 2011-10-26 |
| EP2238458A1 (en) | 2010-10-13 |
| CA2710395A1 (en) | 2009-07-09 |
| SI2238458T1 (sl) | 2012-02-29 |
| AU2008343187A1 (en) | 2009-07-09 |
| CA2710395C (en) | 2016-10-18 |
| US20100268474A1 (en) | 2010-10-21 |
| JP2011508218A (ja) | 2011-03-10 |
| AU2008343177A1 (en) | 2009-07-09 |
| CY1112352T1 (el) | 2015-12-09 |
| PL2238458T3 (pl) | 2012-03-30 |
| WO2009085917A1 (en) | 2009-07-09 |
| BRPI0821051B1 (pt) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farkas et al. | Neurogenic obesity and systemic inflammation following spinal cord injury: a review | |
| Blüher et al. | Effects of a 1‐year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children | |
| Inokuchi-Shimizu et al. | TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis | |
| Sutherland | Linking obesity and asthma | |
| Alvehus et al. | The human visceral fat depot has a unique inflammatory profile | |
| Wray et al. | Plasma concentrations of inflammatory markers in previously laminitic ponies | |
| Phillips et al. | Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype | |
| Fearon et al. | Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis | |
| Shea et al. | The prevalence of metabolically healthy obese subjects defined by BMI and dual‐energy X‐ray absorptiometry | |
| Auyeung et al. | Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men | |
| Zare et al. | The effect of occupational noise exposure on serum cortisol concentration of night-shift industrial workers: a field study | |
| Bollinger et al. | Skeletal muscle myotubes in severe obesity exhibit altered ubiquitin‐proteasome and autophagic/lysosomal proteolytic flux | |
| Muramoto et al. | Angiopoietin-like protein 2 sensitively responds to weight reduction induced by lifestyle intervention on overweight Japanese men | |
| Lueders et al. | The α7β1-integrin accelerates fiber hypertrophy and myogenesis following a single bout of eccentric exercise | |
| Fazeli et al. | Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa | |
| Zhou et al. | Effects of simvastatin on glucose metabolism in mouse MIN6 cells | |
| Sun et al. | Activation of GPR81 by lactate inhibits oscillatory shear stress‐induced endothelial inflammation by activating the expression of KLF2 | |
| Fain et al. | Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women | |
| Xie et al. | Regulator of G protein signaling 2 is a key modulator of airway hyperresponsiveness | |
| Borovcanin et al. | IL-33/ST2 pathway and galectin-3 as a new analytes in pathogenesis and cardiometabolic risk evaluation in psychosis | |
| Skowron et al. | Role of obesity on the thickness of primary cutaneous melanoma | |
| Tumas et al. | Nutritional and immune impairments and their effects on outcomes in early pancreatic cancer patients undergoing pancreatoduodenectomy | |
| Kawashima et al. | Phototherapy reduces serum resistin levels in psoriasis patients | |
| Fatani et al. | The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage | |
| Natanek et al. | Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD |